A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

Stopped early · Phase 2

Conditions studied: Open-Angle Glaucoma, Ocular Hypertension

In brief

The purpose of this study was to assess the effects of total volume and total dose on the safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and 48 mg) in 0.5 mL and 0.8 mL volumes when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Key facts

Study ID

NCT00788541

Run by

Alcon Research

People needed

197

Starts

2008-12-01

Expected to finish

2009-09-01

Last updated by the study team

2012-11-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of Open-Angle Glaucoma or Ocular Hypertension for at least 6 months;
• Other protocol-defined inclusion criteria may apply.

You may not qualify if…

• Prior angle surgery in the study eye, severe visual field loss in either eye;
• Other protocol-defined exclusion criteria may apply.

Where it is running

• Contact Alcon Call Center For Trial Locations — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.